Modality
siRNA
MOA
BETi
Target
AuroraA
Pathway
Angiogenesis
PTSD
Development Pipeline
Preclinical
Apr 2022
→ Oct 2029
PreclinicalCurrent
NCT04526583
1,064 pts·PTSD
2025-04→2027-09·Not yet recruiting
NCT08432357
819 pts·PTSD
2022-04→2029-10·Terminated
1,883 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-031.4y awayInterim· PTSD
2029-10-013.5y awayInterim· PTSD
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2027-09-03 · 1.4y away
PTSD
Interim
2029-10-01 · 3.5y away
PTSD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04526583 | Preclinical | PTSD | Not yet recr... | 1064 | MRD |
| NCT08432357 | Preclinical | PTSD | Terminated | 819 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| COR-9456 | Corcept | Preclinical | TIGIT |